Spots Global Cancer Trial Database for Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC
Official Title: Randomized Clinical Study of Maintenance Therapy With Immunomodulator MGN1703 in Patients With Extensive Disease Small Cell Lung Cancer After Platinum-Based First-Line Therapy
Study ID: NCT02200081
Conditions
Study Description
Brief Summary: Evaluation of efficacy and safety of MGN1703 administered twice weekly subcutaneously (SC) as maintenance treatment in patients with extensive disease small cell lung cancer (SCLC) who achieved at least a partial response (PR) following platinum-based first-line therapy.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Medizinische Universitaet Innsbruck, Innsbruck, , Austria
Universitair Ziekenhuis Gent, Gent, , Belgium
Thoraxklinik Heidelberg gGmbH, Heidelberg, Baden Württemberg, Germany
Hospital Universitario Fundación Jiménez Díaz, Madrid, , Spain
Contact Details
Name: Veerle Surmont, MD
Affiliation: University Hospital Ghent, Belgium 9000
Role: PRINCIPAL_INVESTIGATOR
Name: Georg Pall, MD
Affiliation: Medizinische Universität Innsbruck, Innere Medizin, Hämatologie und Onkologie
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
